Type
Internal restructuring
Country
World
Region
Location of affected unit(s)
Denmark, other locations
Sector
(10 - 33) Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.1 - Manufacture of basic pharmaceutical products

9,000 jobs
Number of planned job losses
Job loss
Announcement Date
10 September 2025
Employment effect (start)
10 December 2025
Foreseen end date
31 December 2026

Description

Novo Nordisk, the Danish pharmaceutical group, has announced a restructuring programme that will cut 9,000 jobs worldwide within the next few months.

In Denmark, the company plans to cut 5,000 positions Novo Nordisk 2025-DK. The layoffs will primarily affect staff functions such as IT.

According to the company, the reductions are necessary to simplify the organisation, increase agility, and allocate resources to growth areas in diabetes and obesity treatments, amid slowing growth and intensifying competition. The restructuring includes one-off costs of DKK 8 billion in 2025, leading to revised profit expectations. Despite the scale of the cuts, the market responded positively, viewing the move as a sign of strategic decisiveness. Novo’s stock rose 3.7% following the announcement.

Novo Nordisk employs about 78,400 people globally. It has about 80 offices worldwide, and its production sites are located in Denmark, France, China, and the United States.


Sources

Citation

Eurofound (2025), Novo Nordisk, Internal restructuring in World, factsheet number 203354, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/203354.